Sponsors (5)
The bill creates a federal legal path for people exposed to PFAS to obtain medical monitoring and drives more research and industry accountability, but it also increases litigation, regulatory costs, and consumer price pressure and could produce orders based on limited scientific evidence.
People significantly exposed to PFAS (including low-income individuals, rural residents, and patients with chronic conditions) can sue in federal court to obtain court-ordered medical monitoring and other relief, creating a clear federal legal pathway for relief.
Individuals with measurable PFAS in their bodies are presumed to be significantly exposed, easing proof for medical monitoring claims and lowering the evidentiary burden on plaintiffs.
Defendants are required to pay for testing and rebuttal testing used to establish exposure, reducing out-of-pocket costs for plaintiffs and making it easier for low-income and affected communities to pursue claims.
Manufacturers facing new federal liability and compliance costs are likely to pass those costs to consumers, raising prices and affecting middle-class families, taxpayers, and small-business customers.
Expanded federal litigation over PFAS will increase court caseloads and legal costs, potentially delaying relief, raising litigation and insurance costs, and straining federal and local courts.
Broad liability could deter some beneficial industrial or consumer uses of PFAS-containing products or slow production, harming affected industries and workers and possibly leading to job losses or reduced product availability.
Based on analysis of 4 sections of legislative text.
Creates a federal private right of action for significant PFAS exposure and authorizes courts to order manufacturer-funded medical monitoring.
Official title: To amend the Toxic Substances Control Act to codify a Federal cause of action and a type of remedy available for individuals significantly exposed to per- and polyfluoroalkyl substances, to encourage research and accountability for irresponsible discharge of those substances, and for other purposes.
Introduced December 11, 2025 by Madeleine Dean · Last progress December 11, 2025
Creates a new federal private right of action for people significantly exposed to PFAS chemicals and authorizes medical monitoring remedies so exposed individuals can obtain periodic diagnostic care paid by responsible manufacturers. The law defines covered PFAS, establishes presumptions of exposure (including detectable PFAS in blood or proof of manufacturer release into an exposure area for at least one year), allows defendants to rebut those presumptions through testing, and permits courts to lower scientific proof standards or order studies when toxicology data are lacking.